Indications and uses
Helps prevent sunburn.
Zinc Oxide and Titanium Dioxide
- Manufacturer
- Ventura Corporation LTD | Bel Star S.A. (Colombia)
- Effective date
- 2014-01-27
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:37:07
Label at a glance#
ProductLBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (CLAIRE 1) - BEIGE
Active ingredientZinc Oxide, Titanium Dioxide
Label structure17 sections
Dosage and administration
Apply liberally and evenly 15 minutes before sun exposure. Reapply at least every 2 hours. Use a water resistant sunscreen if swimming or sweating. Children under 6 months of age: Ask a doctor Apply stick following the curves of natural lip line. For added definition, use with a lip pencil
Storage and handling
Protect this product in this container form excesive heat and direct sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active Ingredients | Purpose |
|---|---|
| TITANIUM DIOXIDE (5.7%) | Sunscreen |
| ZINC OXIDE (4.9%) | Sunscreen |
Uses
- Helps prevent sunburn.
Warnings
- Skin Cancer / Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging.This product has been shown only to help prevent sunburn, not skin cancer or early skin aging. Rinse with water to remove. If swallowed, get medical help or contact a Poison Control Center right away.
OTC - WHEN USING SECTION
- For external use only.
OTC - DO NOT USE SECTION
- Do not use on damaged or broken skin.
OTC - WHEN USING SECTION
- When using this product keep out of eyes.Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash occurs.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- Apply liberally and evenly 15 minutes before sun exposure.
- Reapply at least every 2 hours.
- Use a water resistant sunscreen if swimming or sweating.
- Children under 6 months of age: Ask a doctor
- Apply stick following the curves of natural lip line. For added definition, use with a lip pencil
Other information
- Protect this product in this container form excesive heat and direct sun.
Inactive ingredients
Mica,dimethicone, polymethylsilsesquioxane, zinc stearate, hdi/trimethylol hexyllactone crosspolymer, trimethylsiloxysilicate, caprylic/capric triglyceride, perfluorooctyl triethoxysilane, tocopheryl acetate, hydrogen dimethicone, phenoxyethanol, cetyl peg/ppg-10/1 dimethicone, polyglyceryl-4 isostearate, alumina, hexyl laurate, parfum (fragrance), caprylyl glycol, triethoxycaprylylsilane, chlorphenesin, crithmum maritimum extract, ceramide 3.
May contain:
CI 77492 (iron oxides), CI 77491 (iron oxides), CI 77499 (iron oxides), CI 77891 (titanium dioxide ).
SPL UNCLASSIFIED SECTION
P.R.: Dist by Ventura Corp, Ltd., San Juan, Puerto Rico 00926.
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (CLAIRE 1) - Beige
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (CLAIRE 2) - Beige
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (CLAIRE 3) - Beige
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (CLAIRE 4) - Beige
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (MEDIUM 5) - Brown
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (MEDIUM 6) - Brown
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (MEDIUM 7) - Brown
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (OBSCURE 8) - Brown
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
PRINCIPAL DISPLAY PANEL - 12 g Case Box - (OBSCURE 9) - Brown
EFFET PARFAIT
long lasting compact powder SPF 15
Net Weigth 0.42 oz. (12 g)
L'BEL
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Titanium Dioxide | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| Titanium Dioxide | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| Zinc Oxide | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| .ALPHA.-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 1 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| CAPRYLYL GLYCOL | INACTIVE INGREDIENT | 00YIU5438U | 1 | |
| CERAMIDE 3 | INACTIVE INGREDIENT | 4370DF050B | 1 | |
| CHLORPHENESIN | INACTIVE INGREDIENT | I670DAL4SZ | 1 | |
| CRITHMUM MARITIMUM | INACTIVE INGREDIENT | J7IHY79BKY | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| HEXYL LAURATE | INACTIVE INGREDIENT | 4CG9F9W01Q | 1 | |
| MEDIUM-CHAIN TRIGLYCERIDES | INACTIVE INGREDIENT | C9H2L21V7U | 1 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 1 | |
| PERFLUOROOCTYL TRIETHOXYSILANE | INACTIVE INGREDIENT | 814P46684U | 1 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| POLYGLYCERYL-4 ISOSTEARATE | INACTIVE INGREDIENT | 820DPX33S7 | 1 | |
| TRIETHOXYCAPRYLYLSILANE | INACTIVE INGREDIENT | LDC331P08E | 1 | |
| ZINC STEARATE | INACTIVE INGREDIENT | H92E6QA4FV | 1 |
Products#
Every source-derived product name is available through these pages.
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (CLAIRE 1) - BEIGE
- Zinc Oxide and Titanium Dioxide
- Zinc Oxide
- Titanium Dioxide
- MICA
- DIMETHICONE
- ZINC STEARATE
- MEDIUM-CHAIN TRIGLYCERIDES
- PERFLUOROOCTYL TRIETHOXYSILANE
- .ALPHA.-TOCOPHEROL ACETATE
- PHENOXYETHANOL
- POLYGLYCERYL-4 ISOSTEARATE
- ALUMINUM OXIDE
- HEXYL LAURATE
- CAPRYLYL GLYCOL
- TRIETHOXYCAPRYLYLSILANE
- CHLORPHENESIN
- CRITHMUM MARITIMUM
- CERAMIDE 3
- FERRIC OXIDE YELLOW
- FERRIC OXIDE RED
- FERROSOFERRIC OXIDE
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (CLAIRE 2) - BEIGE
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (CLAIRE 3) - BEIGE
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (CLAIRE 4) - BEIGE
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (MEDIUM 5) - BROWN
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (MEDIUM 6) - BROWN
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (MEDIUM 7) - BROWN
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (OBSCURE 8) - BROWN
- LBEL EFFET PARFAIT Polvos Compactos de Larga Duracion para rostro FPS 15 /Long Lasting Compact SPF 15 (OBSCURE 9) - BROWN
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | FILM / BUCCAL | 0.27 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY / TOPICAL | 540 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, EXTENDED RELEASE / ORAL | 5 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / SUBLINGUAL | 1 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CAPSULE / ORAL | 4771 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 990.3 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | OINTMENT / TOPICAL | 20 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED PELLETS / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, COATED / ORAL | 1 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, EXTENDED RELEASE / ORAL | 8 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, FILM COATED / ORAL | 6 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE / ORAL | 14 mg | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | CAPSULE / ORAL | 2 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | CAPSULE / ORAL | 2.04 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, FILM COATED / ORAL | 3 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | POWDER / SUBLINGUAL | 2 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, CHEWABLE / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / BUCCAL | 0.4 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | SYRUP / ORAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | SUSPENSION, EXTENDED RELEASE / ORAL | 2.7 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY, METERED / SUBLINGUAL | 110 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 3.6 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | LOTION / TOPICAL | 1 %w/w | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | POWDER / RESPIRATORY (INHALATION) | 0.04 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | LOTION / TOPICAL | 7 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | DROPS / ORAL | NA | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, COATED / ORAL | NA | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, COATED / ORAL | 0.11 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, DELAYED RELEASE / ORAL | 6 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, EXTENDED RELEASE / ORAL | 7 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, DELAYED RELEASE / ORAL | 7 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | TABLET, EXTENDED RELEASE / ORAL | 36 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | POWDER, FOR SUSPENSION / ORAL | 1 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | SUSPENSION / ORAL | 6 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SOLUTION / ORAL | 5566 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SUSPENSION / ORAL | 10170 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | TABLET / ORAL | 0.5 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, DELAYED RELEASE / ORAL | 14 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, FILM COATED / ORAL | 0.2 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | GRANULE, FOR SUSPENSION / ORAL | 11 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CREAM / TOPICAL | 3300 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | POWDER / TOPICAL | 0.1 mg/mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, DELAYED RELEASE / ORAL | 3 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, DELAYED RELEASE / ORAL | 37 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, EXTENDED RELEASE / ORAL | 1.49 mg | ||
| ZINC STEARATE | ZINC STEARATE | H92E6QA4FV | TABLET / BUCCAL | 2.5 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM / TOPICAL | 57 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, EXTENDED RELEASE / ORAL | 0.37 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 8ec6969e-3a81-4cd9-819d-d7cc97b68c6b | 66b28743-1477-462a-9842-bce9e9df2387 | 2014-01-27 | Warnings | 8ec6969e-3a81-4cd9-819d-d7cc97b68c6b 66b28743-1477-462a-9842-bce9e9df2387 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.